Unbiased mapping of cereblon neosubstrate landscape by high-throughput proteomics

Abstract Molecular glue degraders (MGDs) are small molecules that co-opt the ubiquitin-proteasome system to induce degradation of target proteins, including those considered undruggable. Their discovery remains challenging due to the lack of rational design strategies and limited throughput of unbia...

Full description

Saved in:
Bibliographic Details
Main Authors: Martin Steger, Gisele Nishiguchi, Qiong Wu, Bjoern Schwalb, Bachuki Shashikadze, Kevin McGowan, Marisa Actis, Anup Aggarwal, Zhe Shi, Jeanine Price, Anand Mayasundari, Lei Yang, Anastasia H. Bednarz, Sophie Machata, Tobias Graef, Denis Bartoschek, Vadim Demichev, Uli Ohmayer, Jun Yang, Henrik Daub, Zoran Rankovic
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-62829-0
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849226154309844992
author Martin Steger
Gisele Nishiguchi
Qiong Wu
Bjoern Schwalb
Bachuki Shashikadze
Kevin McGowan
Marisa Actis
Anup Aggarwal
Zhe Shi
Jeanine Price
Anand Mayasundari
Lei Yang
Anastasia H. Bednarz
Sophie Machata
Tobias Graef
Denis Bartoschek
Vadim Demichev
Uli Ohmayer
Jun Yang
Henrik Daub
Zoran Rankovic
author_facet Martin Steger
Gisele Nishiguchi
Qiong Wu
Bjoern Schwalb
Bachuki Shashikadze
Kevin McGowan
Marisa Actis
Anup Aggarwal
Zhe Shi
Jeanine Price
Anand Mayasundari
Lei Yang
Anastasia H. Bednarz
Sophie Machata
Tobias Graef
Denis Bartoschek
Vadim Demichev
Uli Ohmayer
Jun Yang
Henrik Daub
Zoran Rankovic
author_sort Martin Steger
collection DOAJ
description Abstract Molecular glue degraders (MGDs) are small molecules that co-opt the ubiquitin-proteasome system to induce degradation of target proteins, including those considered undruggable. Their discovery remains challenging due to the lack of rational design strategies and limited throughput of unbiased proteome-wide screening approaches. To address this gap, we develop a high-throughput proteomics platform based on label-free, data-independent acquisition mass spectrometry (DIA-MS), enabling integrated proteomics and ubiquitinomics profiling. Screening a diverse set of 100 cereblon (CRBN)-recruiting ligands on this platform leads to identification of a broad array of novel degraders and neosubstrates. Subsequent hit validation and structure-degradation relationship analyses guided by global proteomics reveal highly selective and potent phenyl glutarimide-based degraders targeting previously uncharacterized neosubstrates such as KDM4B, G3BP2 and VCL; none of which contain the classical CRBN β-hairpin degron. These findings underscore the power of unbiased high-throughput proteomics in MGD drug discovery and reveal a substantially expanded CRBN neosubstrate landscape beyond that defined by classical immunomodulatory imid drugs (IMiDs).
format Article
id doaj-art-a6fa43e264d645fbb54f04e431c2d938
institution Kabale University
issn 2041-1723
language English
publishDate 2025-08-01
publisher Nature Portfolio
record_format Article
series Nature Communications
spelling doaj-art-a6fa43e264d645fbb54f04e431c2d9382025-08-24T11:38:46ZengNature PortfolioNature Communications2041-17232025-08-0116111610.1038/s41467-025-62829-0Unbiased mapping of cereblon neosubstrate landscape by high-throughput proteomicsMartin Steger0Gisele Nishiguchi1Qiong Wu2Bjoern Schwalb3Bachuki Shashikadze4Kevin McGowan5Marisa Actis6Anup Aggarwal7Zhe Shi8Jeanine Price9Anand Mayasundari10Lei Yang11Anastasia H. Bednarz12Sophie Machata13Tobias Graef14Denis Bartoschek15Vadim Demichev16Uli Ohmayer17Jun Yang18Henrik Daub19Zoran Rankovic20NEOsphere Biotechnologies GmbHDepartment of Chemical Biology and Therapeutics, St. Jude Children’s Research HospitalDepartment of Surgery, St. Jude Children’s Research HospitalNEOsphere Biotechnologies GmbHNEOsphere Biotechnologies GmbHDepartment of Chemical Biology and Therapeutics, St. Jude Children’s Research HospitalDepartment of Chemical Biology and Therapeutics, St. Jude Children’s Research HospitalDepartment of Chemical Biology and Therapeutics, St. Jude Children’s Research HospitalDepartment of Chemical Biology and Therapeutics, St. Jude Children’s Research HospitalDepartment of Chemical Biology and Therapeutics, St. Jude Children’s Research HospitalDepartment of Chemical Biology and Therapeutics, St. Jude Children’s Research HospitalDepartment of Chemical Biology and Therapeutics, St. Jude Children’s Research HospitalNEOsphere Biotechnologies GmbHNEOsphere Biotechnologies GmbHNEOsphere Biotechnologies GmbHNEOsphere Biotechnologies GmbHDepartment of Biochemistry, Charité – Universitätsmedizin BerlinNEOsphere Biotechnologies GmbHDepartment of Surgery, St. Jude Children’s Research HospitalNEOsphere Biotechnologies GmbHDepartment of Chemical Biology and Therapeutics, St. Jude Children’s Research HospitalAbstract Molecular glue degraders (MGDs) are small molecules that co-opt the ubiquitin-proteasome system to induce degradation of target proteins, including those considered undruggable. Their discovery remains challenging due to the lack of rational design strategies and limited throughput of unbiased proteome-wide screening approaches. To address this gap, we develop a high-throughput proteomics platform based on label-free, data-independent acquisition mass spectrometry (DIA-MS), enabling integrated proteomics and ubiquitinomics profiling. Screening a diverse set of 100 cereblon (CRBN)-recruiting ligands on this platform leads to identification of a broad array of novel degraders and neosubstrates. Subsequent hit validation and structure-degradation relationship analyses guided by global proteomics reveal highly selective and potent phenyl glutarimide-based degraders targeting previously uncharacterized neosubstrates such as KDM4B, G3BP2 and VCL; none of which contain the classical CRBN β-hairpin degron. These findings underscore the power of unbiased high-throughput proteomics in MGD drug discovery and reveal a substantially expanded CRBN neosubstrate landscape beyond that defined by classical immunomodulatory imid drugs (IMiDs).https://doi.org/10.1038/s41467-025-62829-0
spellingShingle Martin Steger
Gisele Nishiguchi
Qiong Wu
Bjoern Schwalb
Bachuki Shashikadze
Kevin McGowan
Marisa Actis
Anup Aggarwal
Zhe Shi
Jeanine Price
Anand Mayasundari
Lei Yang
Anastasia H. Bednarz
Sophie Machata
Tobias Graef
Denis Bartoschek
Vadim Demichev
Uli Ohmayer
Jun Yang
Henrik Daub
Zoran Rankovic
Unbiased mapping of cereblon neosubstrate landscape by high-throughput proteomics
Nature Communications
title Unbiased mapping of cereblon neosubstrate landscape by high-throughput proteomics
title_full Unbiased mapping of cereblon neosubstrate landscape by high-throughput proteomics
title_fullStr Unbiased mapping of cereblon neosubstrate landscape by high-throughput proteomics
title_full_unstemmed Unbiased mapping of cereblon neosubstrate landscape by high-throughput proteomics
title_short Unbiased mapping of cereblon neosubstrate landscape by high-throughput proteomics
title_sort unbiased mapping of cereblon neosubstrate landscape by high throughput proteomics
url https://doi.org/10.1038/s41467-025-62829-0
work_keys_str_mv AT martinsteger unbiasedmappingofcereblonneosubstratelandscapebyhighthroughputproteomics
AT giselenishiguchi unbiasedmappingofcereblonneosubstratelandscapebyhighthroughputproteomics
AT qiongwu unbiasedmappingofcereblonneosubstratelandscapebyhighthroughputproteomics
AT bjoernschwalb unbiasedmappingofcereblonneosubstratelandscapebyhighthroughputproteomics
AT bachukishashikadze unbiasedmappingofcereblonneosubstratelandscapebyhighthroughputproteomics
AT kevinmcgowan unbiasedmappingofcereblonneosubstratelandscapebyhighthroughputproteomics
AT marisaactis unbiasedmappingofcereblonneosubstratelandscapebyhighthroughputproteomics
AT anupaggarwal unbiasedmappingofcereblonneosubstratelandscapebyhighthroughputproteomics
AT zheshi unbiasedmappingofcereblonneosubstratelandscapebyhighthroughputproteomics
AT jeanineprice unbiasedmappingofcereblonneosubstratelandscapebyhighthroughputproteomics
AT anandmayasundari unbiasedmappingofcereblonneosubstratelandscapebyhighthroughputproteomics
AT leiyang unbiasedmappingofcereblonneosubstratelandscapebyhighthroughputproteomics
AT anastasiahbednarz unbiasedmappingofcereblonneosubstratelandscapebyhighthroughputproteomics
AT sophiemachata unbiasedmappingofcereblonneosubstratelandscapebyhighthroughputproteomics
AT tobiasgraef unbiasedmappingofcereblonneosubstratelandscapebyhighthroughputproteomics
AT denisbartoschek unbiasedmappingofcereblonneosubstratelandscapebyhighthroughputproteomics
AT vadimdemichev unbiasedmappingofcereblonneosubstratelandscapebyhighthroughputproteomics
AT uliohmayer unbiasedmappingofcereblonneosubstratelandscapebyhighthroughputproteomics
AT junyang unbiasedmappingofcereblonneosubstratelandscapebyhighthroughputproteomics
AT henrikdaub unbiasedmappingofcereblonneosubstratelandscapebyhighthroughputproteomics
AT zoranrankovic unbiasedmappingofcereblonneosubstratelandscapebyhighthroughputproteomics